As COVID-19 Successes Fuel R&D, Efforts Focus On mRNA Optimization
In the third part of this special focus on mRNA manufacturing, In Vivo looks at the many directions mRNA platforms can expand, with a major focus on optimizing cellular microenvironments for safety and efficacy.
You may also be interested in...
They’re all probing the drug shortage problem, each with a different line of inquiry: the Federal Trade Commission and the Health and Human Services Department, House Oversight Committee Democrats, and the bipartisan leadership of the Senate Finance Committee.
A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.
Groups representing contract manufacturers and cell and gene therapy developers criticized agency’s actions forcing biologics sponsors to grapple with chemistry, manufacturing and controls challenges instead of relying on contract manufacturers’ proprietary technologies.